CHRS Stock Analysis: Why Coherus BioSciences Inc Scored 33% in Stock Value Finder

Coherus BioSciences Inc (CHRS): A Detailed Educational Stock Research Review

Overview of Coherus BioSciences Inc (CHRS)

Coherus BioSciences Inc (CHRS) is a biotechnology company operating in the healthcare sector. Biotechnology firms typically focus on developing innovative medical treatments, therapies, or diagnostic tools, often involving significant research and development (R&D) investments. This educational review from StockValueFinder.com examines CHRS using a disciplined, number-driven approach to help investors understand how to evaluate stocks based on fundamental and technical metrics.

At the time of this analysis, CHRS trades at $1.05 per share. The StockValueFinder score for CHRS is 33%, resulting in an "AVOID" rating. This score reflects a combination of financial health, valuation, and trend metrics, which we will explore in detail. This article is designed to teach readers how to interpret these metrics, not to recommend buying or selling CHRS.

Why the StockValueFinder Score Matters

The StockValueFinder score is a composite metric that evaluates a stock across multiple dimensions: earnings consistency, capital efficiency, financial safety, valuation, and trend. Each metric is assigned a pass or fail based on predefined thresholds, and the overall score reflects the percentage of tests passed. A score of 33% means CHRS passed only one-third of the evaluated tests, which is why it received an "AVOID" rating.

Scores are not predictions of future performance. Instead, they provide a structured way to compare stocks based on historical and current financial data. For example, a score of 80% or higher might indicate a stock that meets most criteria for financial health and valuation discipline, while a score below 50% suggests areas of concern that warrant further investigation.

EPS Strength and Consistency

What Is EPS?

Earnings per share (EPS) measures a company's profitability on a per-share basis. It is calculated by dividing net income by the number of outstanding shares. Consistent or growing EPS over time is often a sign of a stable or improving business, while erratic or declining EPS may indicate operational challenges.

Why EPS Consistency Matters

StockValueFinder evaluates EPS consistency to assess whether a company has a track record of generating reliable earnings. Companies with volatile EPS may struggle with unpredictable revenue streams, high costs, or competitive pressures. For example, a company with EPS of $1.00, $1.20, and $1.15 over three consecutive years demonstrates more stability than one with EPS of $0.50, -$0.20, and $1.00.

CHRS EPS Test Result

For CHRS, the EPS test result is "Did not pass." This means the system did not identify a consistent or positive EPS history based on the available data. Without exact EPS figures, we cannot analyze the specific earnings trends, but the failure of this test suggests that CHRS has not demonstrated the earnings stability that StockValueFinder typically looks for in high-quality stocks.

Educational Example

Consider two hypothetical companies

– **Company A**: EPS of $0.80, $0.85, and $0.90 over three years. – **Company B**: EPS of $0.50, -$0.30, and $1.20 over three years.

Company A passes the EPS consistency test because its earnings are stable and growing modestly. Company B fails because its earnings are volatile, including a loss in one year. This volatility makes it harder to predict future performance.

ROIC and Capital Efficiency

What Is ROIC?

Return on invested capital (ROIC) measures how effectively a company uses its capital to generate profits. It is calculated as: **ROIC = (Net Operating Profit After Tax) / (Total Invested Capital)**

ROIC helps investors understand whether a company is deploying its capital efficiently. A higher ROIC indicates that the company is generating more profit per dollar of invested capital.

What Is a Strong ROIC?

StockValueFinder generally prefers ROIC of 10% or higher. This threshold is based on the idea that companies should generate returns above their cost of capital to create value for shareholders. For example: – A company with a 15% ROIC is typically using its capital more efficiently than one with a 4% ROIC. – A negative ROIC, such as -168.02%, indicates that the company is losing money on its invested capital.

CHRS ROIC Analysis

CHRS has an ROIC of -168.02%. This is an extremely weak result, far below the 10% threshold. A negative ROIC means that the company is not generating enough profit to cover its cost of capital. In practical terms, this suggests that CHRS is struggling to turn its investments into profitable operations, which is a significant red flag for investors.

Educational Example

Imagine two companies

– **Company X**: ROIC of 12%. This company generates $12 in profit for every $100 of invested capital. – **Company Y**: ROIC of -50%. This company loses $50 for every $100 of invested capital.

Company X passes the ROIC test because it is creating value for shareholders. Company Y fails because it is destroying value, which is unsustainable in the long run.

Interest Coverage and Financial Safety

What Is Interest Coverage?

Interest coverage measures a company's ability to pay the interest on its debt. It is calculated as: **Interest Coverage = (Earnings Before Interest and Taxes) / (Interest Expense)**

A higher interest coverage ratio indicates that a company can comfortably meet its interest obligations, while a lower ratio suggests potential financial strain.

What Is a Strong Interest Coverage?

StockValueFinder prefers an interest coverage ratio of 6 or higher. This means the company earns at least six times its annual interest expense, providing a margin of safety. For example: – A company with interest coverage of 8x is in a stronger financial position than one with 2x coverage. – A company with interest coverage below 1x may struggle to pay its interest, risking default.

CHRS Interest Coverage Test Result

For CHRS, the interest coverage test result is "Did not pass." This means the company's interest coverage ratio is below the preferred threshold of 6. Without the exact interest coverage number, we cannot analyze the specific level of financial strain, but the failure of this test suggests that CHRS may be at risk of financial instability if it carries significant debt.

Educational Example

Consider two companies

– **Company M**: Interest coverage of 10x. This company earns $10 for every $1 of interest expense, indicating strong financial health. – **Company N**: Interest coverage of 1.5x. This company earns only $1.50 for every $1 of interest expense, which is risky if earnings decline.

Company M passes the interest coverage test, while Company N fails because it lacks a sufficient buffer to cover its interest payments.

Debt Payback and Balance Sheet Discipline

What Is Debt Payback?

Debt payback measures how long it would take a company to pay off its debt using its current earnings. It is calculated as: **Debt Payback Years = (Total Debt) / (Annual Free Cash Flow)**

A shorter debt payback period indicates a stronger balance sheet, as the company can quickly eliminate its debt if needed.

What Is a Strong Debt Payback?

StockValueFinder prefers a debt payback period of 3 years or less. This threshold ensures that the company can manage its debt without overleveraging. For example: – A debt payback of 1.5 years is more attractive than 7 years, as it suggests the company can pay off its debt relatively quickly. – A negative debt payback, such as -0.27 years, indicates that the company is not generating positive free cash flow, making it impossible to pay down debt.

CHRS Debt Payback Analysis

CHRS has a debt payback period of -0.27 years. This negative value means the company is not generating enough free cash flow to cover its debt obligations. While the test result is marked as "Passed," this is likely due to the negative value being interpreted as a non-issue (since the company cannot pay down debt with negative cash flow). However, in practical terms, a negative debt payback is a significant weakness, as it suggests the company is not financially stable enough to manage its debt.

Educational Example

Imagine two companies

– **Company P**: Debt payback of 2 years. This company generates enough free cash flow to pay off its debt in two years. – **Company Q**: Debt payback of -1 year. This company does not generate positive free cash flow, making it impossible to pay down debt.

Company P passes the debt payback test, while Company Q fails because it lacks the cash flow to manage its debt.

P/E Ratio and Valuation Discipline

What Is P/E Ratio?

The price-to-earnings (P/E) ratio measures a company's stock price relative to its earnings per share. It is calculated as: **P/E Ratio = (Stock Price) / (Earnings Per Share)**

A lower P/E ratio may indicate that a stock is undervalued, while a higher P/E ratio may suggest overvaluation. However, P/E ratios must be interpreted in the context of the company's growth prospects, industry norms, and overall financial health.

What Is a Strong P/E Ratio?

StockValueFinder prefers a P/E ratio of 15 or lower for valuation discipline. This threshold helps investors avoid overpaying for stocks, especially in industries with high growth expectations. For example: – A P/E of 8 may be more attractive than a P/E of 40, assuming the company's fundamentals are sound. – A negative P/E ratio, such as -0.74, indicates that the company is not profitable, making the P/E ratio meaningless in traditional valuation terms.

CHRS P/E Ratio Analysis

CHRS has a P/E ratio of -0.74. This negative value means the company is not generating positive earnings, so the P/E ratio cannot be used to assess valuation in the traditional sense. However, StockValueFinder marked this test as "Passed," likely because the negative P/E is not considered overvalued. In practical terms, a negative P/E is a red flag, as it indicates the company is not profitable.

Educational Example

Consider two companies

– **Company R**: P/E of 10. This company's stock price is 10 times its earnings, which may be attractive if the company is growing. – **Company S**: P/E of -5. This company is not profitable, so the P/E ratio is negative and cannot be used for valuation.

Company R passes the P/E test, while Company S fails because it lacks earnings to justify its stock price.

Moving Average Trend and Entry Timing

What Is a Moving Average?

A moving average is a technical indicator that smooths out price data by calculating the average price over a specific period (e.g., 50-day or 200-day moving average). It helps investors identify trends and potential entry or exit points.

Why Trend Matters

StockValueFinder uses moving averages to assess the trend of a stock. A stock trading above its moving average may be in an uptrend, while a stock trading below its moving average may be in a downtrend. Trend analysis is not a guarantee of future performance but can help investors avoid stocks in prolonged downtrends.

CHRS Moving Average Signal

For CHRS, the moving average signal is "SELL / AVOID TREND." This means the stock is trading below its moving averages, indicating a downtrend. The entry signal is marked as "N/A," meaning there is no favorable entry point based on the current trend.

Educational Example

Imagine two stocks

– **Stock T**: Trading above its 50-day and 200-day moving averages, indicating an uptrend. – **Stock U**: Trading below its 50-day and 200-day moving averages, indicating a downtrend.

Stock T may be more attractive for trend-following investors, while Stock U may be avoided until the trend reverses.

Overall Financial Strengths and Weaknesses

Strengths

1. **Debt Payback Test Passed**: While the debt payback period is negative, the test was marked as passed, likely because the system does not penalize negative values in this context. However, this is not a true strength, as the company cannot pay down debt with negative cash flow. 2. **P/E Valuation Test Passed**: The negative P/E ratio was not flagged as overvalued, but this is not a meaningful strength, as the company is not profitable.

Weaknesses

1. **EPS Test Failed**: CHRS did not demonstrate consistent or positive earnings, which is a critical weakness for long-term investors. 2. **ROIC of -168.02%**: The company is not generating returns on its invested capital, indicating poor capital efficiency. 3. **Interest Coverage Test Failed**: The company may struggle to meet its interest obligations, posing a financial risk. 4. **Negative Debt Payback**: The company cannot pay down debt with negative free cash flow, raising concerns about financial stability. 5. **Negative P/E Ratio**: The company is not profitable, making traditional valuation metrics irrelevant. 6. **Moving Average Signal: SELL / AVOID TREND**: The stock is in a downtrend, which may deter trend-following investors.

Risks and Limitations

Financial Risks

1. **Negative Profitability**: CHRS is not generating positive earnings or free cash flow, which is unsustainable in the long run. Companies that consistently lose money may face liquidity issues or require additional financing. 2. **High Debt Risk**: While the debt payback test was marked as passed, the negative debt payback period suggests the company cannot manage its debt without generating positive cash flow. 3. **Interest Coverage Risk**: The failure of the interest coverage test indicates that CHRS may struggle to pay its interest obligations, increasing the risk of default.

Industry Risks

1. **Biotechnology Volatility**: The biotechnology industry is highly competitive and subject to regulatory risks. Companies in this sector often face long development timelines, high R&D costs, and uncertain commercialization outcomes. 2. **Market Sentiment**: Biotechnology stocks can be highly sensitive to market sentiment, clinical trial results, and regulatory approvals. Negative news can lead to significant price swings.

Limitations of This Analysis

1. **Lack of Exact EPS and Interest Coverage Data**: Without exact numbers, we cannot fully analyze the company's earnings trends or debt servicing ability. 2. **No Future Predictions**: This analysis is based on historical and current data. It does not account for potential future developments, such as new product approvals or strategic shifts. 3. **No Consideration of Growth Prospects**: While CHRS has significant weaknesses, some investors may be willing to accept higher risk for potential growth opportunities. This analysis does not evaluate growth prospects.

Educational Conclusion

This educational review of Coherus BioSciences Inc (CHRS) demonstrates how to evaluate a stock using fundamental and technical metrics. The StockValueFinder score of 33% and "AVOID" rating reflect significant weaknesses in earnings consistency, capital efficiency, financial safety, and trend.

Key takeaways for investors

1. **EPS Consistency**: Look for companies with stable or growing earnings. CHRS failed this test, indicating potential operational challenges. 2. **ROIC**: A strong ROIC (10% or higher) suggests efficient capital use. CHRS's ROIC of -168.02% is a major red flag. 3. **Interest Coverage**: Companies should comfortably cover their interest obligations (6x or higher). CHRS failed this test, raising financial safety concerns. 4. **Debt Payback**: A debt payback period of 3 years or less is preferred. CHRS's negative debt payback period is a significant weakness. 5. **P/E Ratio**: A P/E of 15 or lower may indicate better valuation discipline. CHRS's negative P/E ratio reflects its lack of profitability. 6. **Trend Analysis**: Moving averages can help identify trends. CHRS is in a downtrend, which may deter trend-following investors.

This article is not a recommendation to buy or sell CHRS. It is designed to teach investors how to evaluate stocks using disciplined, number-driven criteria. Always conduct your own research and consider your financial goals and risk tolerance before making investment decisions.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

---

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings